Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2929–2952 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Aging
Interventions: Walking, HAPA Behavior Change Counseling; Behavioral · Other
Lead sponsor: Iowa State University; Other
Eligibility: 65 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Patients With Compensated Liver Cirrhosis
Interventions: Methacetin Breath Test; Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • Durham, North Carolina • Richmond, Virginia

Conditions: Cancer
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Normal Blood Pressure, Controlled Hypertension, Uncontrolled Hypertension
Interventions: ABPMPro, Spacelabs Ambulatory Blood Pressure Monitoring, Aktiia Blood Pressure, LiveMetric, Bpro; Device
Lead sponsor: Stephen Juraschek; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Hypertension
Interventions: Sertraline, Candesartan; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 60 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension, Hyperglycemia, Dyslipidemia, Metabolic Syndrome, Obesity &Amp; Overweight, Diabetes, Hyperlipidemia, Emergency Medicine
Interventions: Composite intervention to address MetS; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension, Overweight or Obesity
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 28
States / cities: Phoenix, Arizona • Covina, California • Northridge, California + 24 more

Conditions: Blood Pressure
Interventions: Radiation Dose 25 Gy, Radiation Dose 50 Gy; Radiation
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Ocular Dryness, Ocular Irritation, Open-Angle Glaucoma, Ocular Hypertension
Interventions: Travaprost without BAC (Travatan Z); Drug
Lead sponsor: United States Air Force; Federal
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions: Oral Ifetroban, Oral Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more

Conditions: Diabetes, Hypertension
Interventions: Reminder, Fresh start, Fresh start framing; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 13,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions: Lifestyle Modification; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 12 Years and older
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypertension
Interventions: Sildenafil Oral Suspension, Placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypertension, Primary Care
Interventions: Provider nudge, Patient nudge, Pharmacist Virtual Visit; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypertension
Interventions: Aliskiren, Aliskiren plus placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Preeclampsia
Interventions: Sample collection; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions: Problem List Suggestion; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,386 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Actelion; Industry
Eligibility: 3 Months and older
Enrollment: 3,515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 54
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 39 more

Conditions: Glaucoma, Primary Open Angle
Interventions: oxygen inhalation, Adaptive optics imaging; Other · Device
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: Iloprost Inhalation Solution (Ventavis); Drug
Lead sponsor: Actelion; Industry
Eligibility: 3 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Denver, Colorado • New York, New York

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost Sodium Modified Release; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Torrance, California • Oakbrook Terrace, Illinois • New York, New York + 3 more

Conditions: Hypertension
Interventions: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Pulmonary Arterial Hypertension
Interventions: ACT-050089, Placebo; Drug · Other
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension

Assessing Portal Hypertension With Methacetin Breath Test

Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review

Wearable Evaluation of Ambulatory Readings for Blood Pressure

Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Renal Denervation in Patients With Uncontrolled Blood Pressure

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Fresh Start Experiment

Peru Longitudinal Study

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

Exosome Cargo From Preeclampsia Patients

Improving Quality by Maintaining Accurate Problems in the EHR

REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management

Adaptive Optics Retinal Imaging

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Tezosentan in Patients With Pulmonary Arterial Hypertension